This was the stock's fourth consecutive day of losses.

Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the ...

Becton Dickinson & Co. closed 20.98% short of its 52-week high of $251.99, which the company reached on February 3rd.

Becton, Dickinson and Company stock opened at $227.95 on Tuesday. The firm has a market capitalization of $65.45 billion, a P/E ratio of 37.87, a P/E/G ratio of 1.63 and a beta of 0.35. The ...

In this article, we are going to take a look at where Becton, Dickinson and Company (NYSE:BDX) stands against other best dividend monarchs. Dividend-focused investors are generally well-acquainted ...

As you can see from the chart above the percentage of shares that are sold short for Becton Dickinson has grown since its last report. This does not mean that the stock is going to fall in the ...

In its fourth quarter 2024 investor letter, Generation Global Equity Strategy emphasized stocks such as Becton, Dickinson and Company (NYSE:BDX). Becton, Dickinson and Company (NYSE:BDX ...

Becton, Dickinson & Co (Symbol: BDX) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further ...

Barclays lowered the firm’s price target on Becton Dickinson (BDX) to $261 from $279 and keeps an Overweight rating on the shares. The firm updated its sum-of-the-parts analysis following ...

Becton, Dickinson and Company (NYSE:BDX), a leading global medical technology company, has recently been the subject of intense scrutiny from Wall Street analysts. The company's strategic moves ...

Becton Dickinson gets rating buy in my first coverage of this stock. Macro demand for medtech and surgical supplies could favor this globally diversified firm with an active portfolio and growth ...